Specify a stock or a cryptocurrency in the search bar to get a summary
Ultimovacs ASA
ULTIUltimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway. Address: Ullernchausséen 64, Oslo, Norway, 0379
Analytics
WallStreet Target Price
71.03 NOKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ULTI
Dividend Analytics ULTI
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ULTI
Stock Valuation ULTI
Financials ULTI
Results | 2019 | Dynamics |